Two other drugs, each growing revenue steadily.

A levothyroxine formulation that looks positive (most commonly prescribed drug) A full proven technology platform to deliver hard to administer drugs by a simple injection.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

We have other amazing drugs, Recorlev, Gvoke and more including some drugs yet to be approved.

As the company continues to bring new treatments to market, it is likely that Biocryst will continue to be a leader in the field of rare disease treatment, providing both patients and investors alike with a brighter future.

gets a drug approved and immediately rewards shareholders!!!

A great drug like Orladeyo and this is what we get in terms of stock performance. FAILURES

We have a revenue generating drug thats just achieved 105% YoY growth.

If you want a derisked, undervalued company with an approved potential blockbuster drug that can provide steady and incremental ROI year over year, plus the added bonus of pipeline drugs adding more value in future… this stock will be a keeper

BCX 9930 was a very promising and exciting drug and it probably is.

$BCRX 9 slides in the presentation about why its "hard" to design drugs lmfao. hilarious.

"We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,”

Brags how great drug discovery platform

$BCRX -- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan -- Good news for Orla I guess .

With their Wellness Pro and their Pod, you can manage your pain without taking drugs.